Blog
RSS FeedPosted by Michael Wonder on 04 May 2020
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
1 May 2020 - The reimbursement of the immune checkpoint inhibitors is challenging. ...
Posted by Michael Wonder on 20 Jan 2020
Why cancelling your private health insurance could have unintended consequences
20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...
Posted by Michael Wonder on 01 Nov 2019
Report clearly demonstrates the value of vaccines
1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...
Posted by Michael Wonder on 03 Jun 2019
Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000
3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...
Posted by Michael Wonder on 10 May 2019
What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?
9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health ...
Posted by Michael Wonder on 26 Nov 2018
We're paying $834 million more for health insurance but getting less
26 November 2018 - Australians paid $834 million more for health insurance in 2017-18 compared to the year before, despite ...
Posted by Michael Wonder on 19 Nov 2018
Poor value sees younger people dropping private health insurance
18 November 2018 - Younger people are ditching private health cover or not taking up cover in the first place, ...
Posted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 05 Sep 2018
Publication of final base-case ICERs (ICURs) by health technology assessment agencies
6 September 2018 - The Department of Health is dragging its heels on this issue. ...
Posted by Michael Wonder on 04 Sep 2018
Why aren't final base-case ICERs published in the PBAC Public Summary Documents?
5 September 2018 - The case for not doing so is now very weak. ...
Posted by Michael Wonder on 03 Sep 2018
Medicare-funded cancer genetic tests: a note of caution
3 September 2018 - Clinicians need appropriate education and support in keeping pace with the genomics revolution. ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 26 Jul 2018
Meningococcal vaccine rejected as not being "cost-effective"
25 July 2018 - With five cases of meningococccal disease now confirmed in Tasmania, questions are being asked about why the ...
Posted by Michael Wonder on 25 Jan 2018
Value based pricing: l'enfant terrible?
25 January 2018 - Concern over pricing of pharmaceuticals and other health technologies in both high- and low-income countries is not ...
Posted by Michael Wonder on 13 Jan 2018
Estimating the reference incremental cost-effectiveness ratio for the Australian health system
22 December 2017 - The objective of this study was to estimate the expected incremental cost per quality-adjusted life-year (QALY) ...